Sherie L. Morrison
25Patents
11h-index
34Co-inventors
75Inventor score
Filing activity: Jul 16, 1993 → Sep 14, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5807715A | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin | Chemistry; Metallurgy | 564 | Expired |
| US5977307A | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins | Chemistry; Metallurgy | 193 | Expired |
| US5672683A | Transferrin neuropharmaceutical agent fusion protein | Chemistry; Metallurgy | 150 | Expired |
| US6284536A | Modified immunoglobin molecules and methods for use thereof | Chemistry; Metallurgy | 116 | Expired |
| US6218149A | Antibodies having modified carbohydrate content and methods of preparation and use | Chemistry; Metallurgy | 111 | Expired |
| US9139634B2 | Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities | Chemistry; Metallurgy | 68 | Active |
| US8258263B2 | Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities | Chemistry; Metallurgy | 31 | Active |
| US6300104A | Secretory immunoglobulin produced by single cells and methods for making and using same | Emerging Cross-Sectional Technologies | 26 | Expired |
| US6861572B1 | Production of proteins in eggs | Human Necessities | 23 | Expired |
| US7736652B2 | Antibody fusion proteins: effective adjuvants of protein vaccination | Chemistry; Metallurgy | 15 | Expired |
| US9803021B2 | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities | Chemistry; Metallurgy | 13 | Active |
| US8563692B2 | Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities | Chemistry; Metallurgy | 10 | Active |
| US6043345A | IgE isoforms and methods of use | Chemistry; Metallurgy | 9 | Expired |
| US9534033B2 | Targeted interferons demonstrating potent apoptotic and anti-tumor activities | Chemistry; Metallurgy | 5 | Active |
| US10182984B2 | Targeted interferons demonstrate potent apoptotic and anti-tumor activities | Chemistry; Metallurgy | 3 | Active |
| US10093745B2 | Anti-CSPG4 fusions with interferon for the treatment of malignancy | Chemistry; Metallurgy | 3 | Active |
| US6475749B1 | Rh hybrid antibody | Physics | 3 | Expired |
| US10822427B2 | Anti-CSPG4 fusions with interferon for the treatment of malignancy | Chemistry; Metallurgy | 2 | Active |
| US11136353B2 | Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof | Chemistry; Metallurgy | 2 | Active |
| US10975158B2 | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities | Chemistry; Metallurgy | 2 | Active |
| US11795198B2 | Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof | Chemistry; Metallurgy | 0 | Active |
| US12415843B2 | Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US9611313B2 | Antibody-endostatin fusion protein and its variants | Physics | 0 | Active |
| US7238784B2 | Rh antibody | Physics | 0 | Expired |
| US12162958B2 | Fusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.